0804 GMT - The results of AstraZeneca's upcoming cancer drug trial have the potential to drive consensus forecasts toward the drug maker's 2030 sales target of $80 billion, Berenberg analysts say in a note. The British pharma company expects positive key late-stage trial readouts for its breast cancer drug Datroway, label extensions for its breast cancer drug Enhertu and hypertension treatment baxdrostat. The company guides for high-single-digit revenue growth but should face headwinds from patent expiries, U.S. Medicare drug pricing reform and foreign currency effects, they say. AstraZeneca's share price is back on track after its 2025 outlook eased investor concerns about the prospects for its China business, which is hampered by ongoing corruption investigation against some of its employees. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 26, 2025 03:04 ET (08:04 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。